Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Zydus Cadila COVID...

Zydus Cadila COVID vaccine ZyCoV-D expected to hit market by June: Report

Medical Dialogues TeamWritten by Medical Dialogues Team Published On 2021-05-16T10:30:09+05:30  |  Updated On 20 Aug 2021 11:10 AM GMT
Zydus Cadila COVID vaccine ZyCoV-D expected to hit market by June: Report

Ahmedabad: With a goal of producing 240 million doses per year, Zydus Cadila's ZyCoV-D, a second indigenous covid vaccine, is scheduled to reach the market by June, as per a recent report by The Print.Dr Sharvil Patel, managing director of Zydus Group, informed that the vaccine trial for ZyCoV-D, a plasmid DNA vaccine, is going well. The company intends to submit the data by the end of May...

Ahmedabad: With a goal of producing 240 million doses per year, Zydus Cadila's ZyCoV-D, a second indigenous covid vaccine, is scheduled to reach the market by June, as per a recent report by The Print.

Dr Sharvil Patel, managing director of Zydus Group, informed that the vaccine trial for ZyCoV-D, a plasmid DNA vaccine, is going well. The company intends to submit the data by the end of May and apply for approval in June. He also mentioned that they would begin supplies in June with the ability to produce 10 million (1 crore) doses per month initially, and then find a way to double the potential to 20 million (2 crores) doses per month.

He added that the vaccine trial involved the elderly, people with co-morbidities, and children between the ages of 12 and 17, so it would be an extra benefit.

ZyCoV-D is a DNA vaccine that consists of a DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus. The S protein of the virus includes the receptor-binding domain (RBD), responsible for binding to the human angiotensin-converting enzyme (ACE-2) receptor. As a result, ZyCoV-D acts by preventing the novel coronavirus from entering cells by targeting the main viral membrane protein.

Earlier, the Medical Dialogues team had reported that the firm had initiated Phase III clinical trials of its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D in around 30,000 volunteers after having received permission from the DCGI.

Also Read: Zydus Cadila starts human trails of COVID-19 vaccine ZyCoV-D

Further, it was reported that the Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomized, double-blind placebo-controlled study.

The vaccine was found to be safe and elicited a strong immunogenic response. The trial was reviewed by an independent Data Safety Monitoring Board (DSMB) and reports were submitted to the Central Drugs Standard Control Organisation (CDSCO) regularly for an update on safety outcome.

Patel told The Print that the Phase III vaccine trials would be genuinely indicative of the vaccine's effectiveness against many of the virus's established variants, as various variants have emerged in this pandemic outbreak. As a result, the trial results would be more reflective of effectiveness evidence than any other vaccine.

In addition, he also stated, without naming the firms, that they are in the process of reaching an agreement with one or two Indian manufacturers to increase production. Technology conversion, on the other hand, is a difficult and time-consuming task, he added.

Also Read:Zydus Cadila single dose COVID drug Virafin priced at Rs 11,995 per dose
Zydus Cadila zycov-d DNA vaccine covid-19 vaccine Covid‐19 covid19 
Source : with inputs
Medical Dialogues Team
Medical Dialogues Team

    Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X